At a glance
ClinicalIndex Comparison RecordN/AUnknown· 350 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Circulating Tumor DNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal Cancer:A Prospective, Multicenter,Observational, Single-Blinded Controlled Study
In Brief
An observational study for Colorectal Cancer. Targeting 350 participants across 1 site.
Detailed Summary
By monitoring the serum ctDNA mutational profile using NGS, the present clinical trial aims to elucidate the correlation between the postoperative ctDNA status and the prognosis of patients with early and intermediate-stage colorectal cancer, and explore the possibility of clinical utility of serum ctDNA as a clinical index to predict postoperative relapse.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesChina
CollaboratorsFudan University, Zhejiang University
Timeline
N/AUnknownOverdue
201820192020202120222023202420252026
Enrollment StartAug 2017
First PostedOct 2017
Primary CompletionDec 2019
Study CompletionMar 2020
TodayJul 2026
First PostedOct 17, 2017
Enrollment StartAug 1, 2017
Primary CompletionDec 30, 2019
Study CompletionMar 30, 2020
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 8.7 years ago